Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Docetaxel + Irinotecan + Paclitaxel|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Docetaxel||Taxotere||Docetaxel anhydrous|Docefrez||Antimicrotubule Agent 12||Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (NCI Drug Dictionary).|
|Irinotecan||Camptosar||CPT-11|Onivyde||TOPO1 inhibitor 8||Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov).|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 12 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02564263||Phase III||Pembrolizumab Docetaxel + Irinotecan + Paclitaxel||Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)||Active, not recruiting|
|NCT01822613||Phase Ib/II||Docetaxel + Irinotecan + Paclitaxel Alpelisib + LJM716||Study of Safety and Efficacy of the Combination of LJM716 and BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)||Completed|